Just a day after French pharma major Sanofi denied that the future of its chief executive was under discussion, at a board meeting convened at 8am this morning it decided unanimously to remove Christopher Viehbacher as chief executive of the company. 29 October 2014
Chris Viehbacher, chief executive of French drug major Sanofi, has urged the company’s board to clarify rumors that he is to be dismissed, according to a letter published in French business newspaper Les Echos. 28 October 2014
Belgian regenerative, protective and reconstructive therapy specialist Cardio3 Biosciences has appointed Warren Sherman as chief medical officer. 23 October 2014
UK-based inflammatory disease and cancer specialist Karus Therapeutics has appointed Simon Roitt as head of clinical development and Peter Finan as head of biology. 21 October 2014
Therapeutic antibody specialist AnaptysBio has appointed Marco Londei as chief development officer, leading the preclinical and clinical development of AnaptysBio’s proprietary antibody pipeline. 20 October 2014
German pharma company Grünenthal Group has appointed Sascha Becker as group chief financial officer, commencing in the first quarter of 2015. 20 October 2014
Although life science company boards are recruiting more women, a lack of managing their talent during their career is slowing the progress towards greater diversity, according to life sciences human resources specialist RSA’s biannual survey of non-executive directors. 14 October 2014
Swedish orphan and niche product specialist Pharmalink has appointed Bengt Julander as chairman of the board of directors, replacing Anders Wiklund. 14 October 2014
Japan’s largest drugmaker Takeda Pharmaceutical has appointed John Boslego as senior vice president and head of development for the company’s global vaccine business unit. 8 October 2014
Canadian biopharmaceutical company Aeterna Zentaris has named Philip Theodore as senior vice president, chief administrative officer, general counsel and corporate secretary. 7 October 2014
Satish Jindal has been appointed to lead the discovery of drug candidates from leading academic institutions at Allied-Bristol Life Sciences, a jointly-owned enterprise between Allied Minds and US drug major Bristol-Myers Squibb. 6 October 2014
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024